Introduction

Ventriculoatrial (VA) shunts are life-saving in circumstances where ventriculoperitoneal shunts (VP) have failed. They are at risk for different complications, and more specific of them are cardiopulmonary complications. Currently, there are no standard recommendations concerning screening for risk factors, prophylaxis, or anticoagulation treatment in patients after VA shunt placement. Our study aims to prospectively study the possible role and efficacy of the use of aspirin to increase the survival of shunts in children with VA shunt and avoid secondary morbidity. In this article, the authors describe the interim results of an ongoing prospective study which supports the use of aspirin for VA shunt.

Materials and methods

The study design is prospective. The duration of the study is 2011 onwards and is ongoing. Hospital ethics board clearance and consent from the family were taken before inclusion in the study. All patients who had VA shunt were given a once-a-day low-antiplatelet dose of aspirin 5 mg/kg, from the first postoperative day onwards. Primary endpoints of the study are as follows: (1) major distal end malfunction documented on echocardiography or (2) any cardiac complications associated with the VA shunt catheter.

Results

We have 6 patient since march 2011, who are being followed up. None of the shunts had malfunctioned until the reporting. None of the patients had any cardiac issues reported. The patients are to be followed continually. The present follow-up ranges from 2.5 to 10 years. The patient follow-up is being continued.

Conclusions

Aspirin is a drug with well-accepted safety profile, and its use and our preliminary observation and outcome of the use of aspirin in VA shunt are promising.

中文翻译：

---

我们是否应该在心房分流患者中使用阿司匹林？从其他专业借叶子：替代证据的案例

介绍

在心室腹膜分流器（VP）出现故障的情况下，心室（VA）分流器可以挽救生命。他们有发生不同并发症的风险，其中更具体的是心肺并发症。当前，尚无关于筛查VA分流后患者危险因素，预防或抗凝治疗的标准建议。我们的研究旨在前瞻性研究使用阿司匹林提高VA分流患儿分流存活率并避免继发性发病的可能作用和功效。在本文中，作者描述了一项正在进行的前瞻性研究的中期结果，该研究支持将阿司匹林用于VA分流。

材料和方法

研究设计是前瞻性的。研究持续时间为2011年及以后。在纳入研究前，已获得医院伦理委员会的批准和家人的同意。从术后第一天起，所有接受VA分流的患者每天接受一次低剂量抗阿司匹林5 mg / kg剂量的阿司匹林治疗。研究的主要终点如下：（1）超声心动图记录的主要远端功能异常；或（2）与VA分流导管相关的任何心脏并发症。

结果

自2011年3月以来，我们有6名患者正在接受随访。在报告之前，所有分流器均未发生故障。没有患者报告有任何心脏问题。患者应得到持续跟踪。目前的随访范围为2.5到10年。正在继续对患者进行随访。

结论

阿司匹林是一种具有公认的安全性的药物，其使用以及我们在VA分流器中使用阿司匹林的初步观察和结果是有希望的。